Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
OPHT's Cash to Debt is ranked higher than
80% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. OPHT: No Debt )
OPHT' s 10-Year Cash to Debt Range
Min: 0.4   Max: No Debt
Current: No Debt

Equity to Asset 0.36
OPHT's Equity to Asset is ranked higher than
58% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OPHT: 0.36 )
OPHT' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.36
Current: 0.36

Interest Coverage No Debt
OPHT's Interest Coverage is ranked higher than
83% of the 576 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OPHT: No Debt )
OPHT' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 3.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -176.35
OPHT's Operating margin (%) is ranked higher than
67% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. OPHT: -176.35 )
OPHT' s 10-Year Operating margin (%) Range
Min: 0   Max: 0
Current: -176.35

Net-margin (%) -208.98
OPHT's Net-margin (%) is ranked higher than
65% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. OPHT: -208.98 )
OPHT' s 10-Year Net-margin (%) Range
Min: 0   Max: 0
Current: -208.98

ROE (%) -45.89
OPHT's ROE (%) is ranked higher than
65% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. OPHT: -45.89 )
OPHT' s 10-Year ROE (%) Range
Min: -221.17   Max: -221.17
Current: -45.89

ROA (%) -24.02
OPHT's ROA (%) is ranked higher than
71% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. OPHT: -24.02 )
OPHT' s 10-Year ROA (%) Range
Min: -231.01   Max: -45.96
Current: -24.02

-231.01
-45.96
ROC (Joel Greenblatt) (%) -1049.49
OPHT's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. OPHT: -1049.49 )
OPHT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -65147.62   Max: -16410.03
Current: -1049.49

-65147.62
-16410.03
» OPHT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

OPHT Guru Trades in

Q3 2013

OPHT Guru Trades in Q3 2013

Columbia Wanger 264,000 sh (New)
» More
Q4 2013

OPHT Guru Trades in Q4 2013

Columbia Wanger Sold Out
» More
Q4 2014

OPHT Guru Trades in Q4 2014

Jim Simons 16,300 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with OPHT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 48.31
OPHT's Forward P/E is ranked higher than
91% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OPHT: 48.31 )
N/A
P/B 10.30
OPHT's P/B is ranked higher than
65% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. OPHT: 10.30 )
OPHT' s 10-Year P/B Range
Min: 7.09   Max: 10.71
Current: 10.3

7.09
10.71
P/S 44.20
OPHT's P/S is ranked higher than
72% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. OPHT: 44.20 )
OPHT' s 10-Year P/S Range
Min: 32.64   Max: 49.34
Current: 44.2

32.64
49.34
PFCF 18.00
OPHT's PFCF is ranked higher than
97% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OPHT: 18.00 )
OPHT' s 10-Year PFCF Range
Min: 12.36   Max: 18.69
Current: 18

12.36
18.69
POCF 24.10
OPHT's POCF is ranked higher than
94% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OPHT: 24.10 )
OPHT' s 10-Year POCF Range
Min: 16.69   Max: 25.22
Current: 24.1

16.69
25.22
EV-to-EBIT -20.05
OPHT's EV-to-EBIT is ranked higher than
77% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OPHT: -20.05 )
OPHT' s 10-Year EV-to-EBIT Range
Min: -22.2   Max: -12.7
Current: -20.05

-22.2
-12.7
Current Ratio 19.25
OPHT's Current Ratio is ranked higher than
95% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. OPHT: 19.25 )
OPHT' s 10-Year Current Ratio Range
Min: 0.34   Max: 40.94
Current: 19.25

0.34
40.94
Quick Ratio 19.25
OPHT's Quick Ratio is ranked higher than
95% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. OPHT: 19.25 )
OPHT' s 10-Year Quick Ratio Range
Min: 0.34   Max: 40.94
Current: 19.25

0.34
40.94
Days Sales Outstanding 461.15
OPHT's Days Sales Outstanding is ranked higher than
66% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. OPHT: 461.15 )
OPHT' s 10-Year Days Sales Outstanding Range
Min: 0   Max: 0
Current: 461.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 19.20
OPHT's Price/Net Cash is ranked higher than
78% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. OPHT: 19.20 )
OPHT' s 10-Year Price/Net Cash Range
Min: 4.8   Max: 13.85
Current: 19.2

4.8
13.85
Price/Net Current Asset Value 13.70
OPHT's Price/Net Current Asset Value is ranked higher than
80% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. OPHT: 13.70 )
OPHT' s 10-Year Price/Net Current Asset Value Range
Min: 4.8   Max: 11.95
Current: 13.7

4.8
11.95
Price/Tangible Book 10.30
OPHT's Price/Tangible Book is ranked higher than
71% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. OPHT: 10.30 )
OPHT' s 10-Year Price/Tangible Book Range
Min: 4.74   Max: 8.87
Current: 10.3

4.74
8.87
Price/Median PS Value 1.20
OPHT's Price/Median PS Value is ranked higher than
83% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. OPHT: 1.20 )
OPHT' s 10-Year Price/Median PS Value Range
Min: 0.88   Max: 0.88
Current: 1.2

Earnings Yield (Greenblatt) -5.00
OPHT's Earnings Yield (Greenblatt) is ranked higher than
75% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. OPHT: -5.00 )
OPHT' s 10-Year Earnings Yield (Greenblatt) Range
Min: -5.2   Max: 0
Current: -5

-5.2
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:O2T.Germany,
» More Articles for OPHT

Headlines

Articles On GuruFocus.com
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Weekly 3-Year Low Highlight: VIV, CNHI, WTW, OPHT Nov 17 2013 
Insiders Are Buying Ophthotech Oct 08 2013 


More From Other Websites
Ophthotech Corporation to Present at the Barclays Global Healthcare Conference Mar 03 2015
Ophthotech Corporation to Present at the Barclays Global Healthcare Conference Mar 03 2015
OPHTHOTECH CORP. Files SEC form 10-K, Annual Report Mar 02 2015
Ophthotech Reports Fourth Quarter and Full Year 2014 Financial and Operating Results Feb 25 2015
Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog Feb 23 2015
Ophthotech reports 4Q loss Feb 23 2015
Ophthotech reports 4Q loss Feb 23 2015
OPHTHOTECH CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 23 2015
Ophthotech Reports Fourth Quarter and Full Year 2014 Financial and Operating Results Feb 23 2015
Q4 2014 Ophthotech Corp Earnings Release - Time Not Supplied Feb 23 2015
Celgene Up on Hematology Drug Revlimid's Label Expansion - Analyst Blog Feb 20 2015
Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog Feb 19 2015
Ophthotech Corporation to Announce Fourth Quarter and Full Year 2014 Financial Results and Host... Feb 18 2015
Ophthotech Corporation to Announce Fourth Quarter and Full Year 2014 Financial Results and Host... Feb 18 2015
Coverage initiated on Ophthotech by Chardan Capital Markets Feb 18 2015
Alnylam Reports Narrower Loss in Q4, Focuses on Pipeline - Analyst Blog Feb 13 2015
Genomic Health Loss Narrower than Expected, Revenues Lag - Analyst Blog Feb 11 2015
Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog Feb 10 2015
AMAG's Q4 Loss Narrows Y/Y, Reiterates 2015 Outlook - Analyst Blog Feb 10 2015
Theravance/Glaxo's Asthma Drug Under FDA Panel Review - Analyst Blog Feb 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK